Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Pfizer has initiated a Phase 3 trial for giroctocogene fitelparvovec (PF-07055480), a gene therapy targeting severe hemophilia A. This advancement reflects Pfizer's commitment to developing transformative treatments for rare diseases.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.